The burden of hepatitis C virus in the world, China, India, and the United States from 1990 to 2019

Abstract

Background and aimHepatitis C virus infection can lead to an enormous health burden worldwide. Investigating the changes in HCV-related burden between different countries could provide inferences for disease management. Hence, we aim to explore the temporal tendency of the disease burden associated with HCV infection in China, India, the United States, and the world.MethodsDetailed data on the total burden of disease related to HCV infection were collected from the Global Burden of Disease (GBD) 2019 database. Joinpoint regression models were used to simulate the optimal joinpoints of annual percent changes (APCs). Further analysis of the age composition of each index over time and the relationship between ASRs and the socio-demographic Index (SDI) were explored. Finally, three factors (population growth, population aging, and age-specific changes) were deconstructed for the changes in the number of incidences, deaths, and DALYs.ResultsIt was estimated that 6.2 million new HCV infections, 0.54 million HCV-related deaths, and 15.3 million DALYs worldwide in 2019, with an increase of 25.4, 59.1, and 43.6%, respectively, from 1990, are mainly due to population growth and aging. China experienced a sharp drop in age-standardized rates in 2019, the United States showed an upward trend, and India exhibited a fluctuating tendency in the burden of disease. The incidence was increasing in all locations recently.ConclusionHCV remains a global health concern despite tremendous progress being made. The disease burden in China improved significantly, while the burden in the United States was deteriorating, with new infections increasing recently, suggesting more targeted interventions to be established to realize the 2030 elimination goals.

Hepatocellular carcinoma‑cavernous hemangioma collision tumor: A case report

“…In general, oncogenic viruses do not necessarily lead to the development of cancer; instead it is their interactions with host factors that leads to preneoplastic conditions and subsequently cancer through various mechanisms, such as dysregulation of the immune system ( 16 ). Another common point between the present study and the aforementioned study ( 10 ) is that both patients were from China, which has a high incidence of hepatitis B and C infections compared with other countries ( 17 , 18 ). Furthermore, neither patient had a record of clinical symptoms associated with the tumor, and both collision tumors were discovered incidentally during health examinations.…”

Recent Advances on Targeting Proteases for Antiviral Development

“…Today, against HIV alone there are ten FDA-approved protease inhibitors, while other diseases, such as hypertension, AIDS and cancer, have also benefited by the discovery of inhibitors [ 20 ]. The hepatitis C virus (HCV) is another major infection with an enormous global health burden with no available vaccine, affecting 58 million people worldwide and causing 290,000 deaths annually [ 30 ]. The most notorious HCV drugs, boceprevir 9 and telaprevir 8 , are also peptidomimetic molecules, with the most recent drugs following the same trend [ 31 ] ( Table 1 ).…”

Global trends in hepatitis C-related hepatocellular carcinoma mortality: A public database analysis (1999-2019)

“…In the late 20 th century, there was a significant shift in the etiology of chronic liver disease due to the advent of Hepatitis C infection, which also contributed to a rising trend in the incidence of liver-related malignancies[ 1 ]. Data from the World Health Organization (WHO) indicates that globally, around 58 million individuals are infected with the hepatitis C virus (HCV).…”